These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 29759565)
1. Glucocorticoids as an adjunct to oncologic treatment in solid malignancies - Not an innocent bystander. Maurice-Dror C; Perets R; Bar-Sela G Crit Rev Oncol Hematol; 2018 Jun; 126():37-44. PubMed ID: 29759565 [TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-mediated effects on angiogenesis in solid tumors. Martens B; Drebert Z J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109 [TBL] [Abstract][Full Text] [Related]
3. New dimension of glucocorticoids in cancer treatment. Lin KT; Wang LH Steroids; 2016 Jul; 111():84-88. PubMed ID: 26930575 [TBL] [Abstract][Full Text] [Related]
5. [Pharmacology of glucocorticoids and ENT pathology]. Devillier P Presse Med; 2001 Dec 22-29; 30(39-40 Pt 2):59-69. PubMed ID: 11819915 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. Kluza E; Yeo SY; Schmid S; van der Schaft DW; Boekhoven RW; Schiffelers RM; Storm G; Strijkers GJ; Nicolay K J Control Release; 2011 Apr; 151(1):10-7. PubMed ID: 21130819 [TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of anti-inflammatory agents to tumors. Coimbra M; Kuijpers SA; van Seters SP; Storm G; Schiffelers RM Curr Pharm Des; 2009; 15(16):1825-43. PubMed ID: 19519426 [TBL] [Abstract][Full Text] [Related]
8. Systemic anti-tumor activity of liposomal glucocorticoids. Park K J Control Release; 2011 Apr; 151(1):1. PubMed ID: 21440020 [No Abstract] [Full Text] [Related]
9. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment. Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725 [TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic agents targeting the glucocorticoid receptor for inflammation and cancer. Sommer P; Ray DW Curr Opin Investig Drugs; 2008 Oct; 9(10):1070-7. PubMed ID: 18821468 [TBL] [Abstract][Full Text] [Related]
12. Lead Structures for Applications in Photodynamic Therapy. 6. Temoporfin Anti-Inflammatory Conjugates to Target the Tumor Microenvironment for In Vitro PDT. Rogers L; Sergeeva NN; Paszko E; Vaz GM; Senge MO PLoS One; 2015; 10(5):e0125372. PubMed ID: 25992651 [TBL] [Abstract][Full Text] [Related]
13. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. Ribatti D Immunol Lett; 2013 May; 152(2):83-8. PubMed ID: 23685256 [TBL] [Abstract][Full Text] [Related]
14. Optimized glucocorticoid therapy: teaching old drugs new tricks. Strehl C; Buttgereit F Mol Cell Endocrinol; 2013 Nov; 380(1-2):32-40. PubMed ID: 23403055 [TBL] [Abstract][Full Text] [Related]
15. [Glucocorticoids and their receptor: mechanisms of action and clinical implications]. Roumestan C; Gougat C; Jaffuel D; Mathieu M Rev Med Interne; 2004 Sep; 25(9):636-47. PubMed ID: 15363619 [TBL] [Abstract][Full Text] [Related]
16. The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus. Goulding NJ Curr Opin Pharmacol; 2004 Dec; 4(6):629-36. PubMed ID: 15525555 [TBL] [Abstract][Full Text] [Related]
17. Genomic and nongenomic effects of glucocorticoids. Stahn C; Buttgereit F Nat Clin Pract Rheumatol; 2008 Oct; 4(10):525-33. PubMed ID: 18762788 [TBL] [Abstract][Full Text] [Related]
18. Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Herr I; Gassler N; Friess H; Büchler MW Apoptosis; 2007 Feb; 12(2):271-91. PubMed ID: 17191112 [TBL] [Abstract][Full Text] [Related]
19. Heparanase: From basic research to therapeutic applications in cancer and inflammation. Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844 [TBL] [Abstract][Full Text] [Related]
20. Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment. D'Uva G; Baci D; Albini A; Noonan DM Cancer Treat Rev; 2018 Feb; 63():1-18. PubMed ID: 29197745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]